NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

– EMA submission expected in 2H25 by partner Menarini –

– PREVAIL Phase 3 CVOT remains on track –

-- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet, respectively --

Read more at globenewswire.com